Printer Friendly

Novartis' Cosentyx achieves endpoints in psoriatic arthritis study.

M2 EQUITYBITES-June 13, 2019-Novartis' Cosentyx achieves endpoints in psoriatic arthritis study

(C)2019 M2 COMMUNICATIONS http://www.m2.com

Switzerland-based Novartis' Cosentyx (secukinumab) has achieved its primary and key secondary endpoint in the Maximise study of psoriatic arthritis, it was reported yesterday.

The product is claimed to be the first and only fully-human biologic, which directly restricts interleukin-17A (IL-17A), a cornerstone cytokine engaged in the inflammation and development of PsA, psoriasis, and ankylosing spondylitis.

Maximise is a double-blind, randomised and placebo-controlled phase IIIb study to evaluate the efficacy and safety of an immunosuppressant in the management of axial manifestations of PsA.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Article Type:Clinical report
Date:Jun 13, 2019
Words:112
Previous Article:Boehringer Ingelheim extends collaboration with University of Dundee.
Next Article:Ionis Pharmaceuticals names new President and CEO of Herman and Associates.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters